학술논문
Comparative evaluation of efficacy, pharmacodynamics, and safety of Hetero's adalimumab (Mabura®, Hetero Biopharma Ltd.) and reference adalimumab (Humira®, Abbvie Inc.) in patients with active rheumatoid arthritis on concomitant methotrexate therapy
Document Type
Article
Author
Source
In: BMC Rheumatology . (BMC Rheumatology, 4 June 2020, 4(1))
Subject
Language
English
ISSN
25201026